Dieter Koeberle

3.3k total citations
87 papers, 2.3k citations indexed

About

Dieter Koeberle is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Dieter Koeberle has authored 87 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 21 papers in Surgery. Recurrent topics in Dieter Koeberle's work include Colorectal Cancer Treatments and Studies (34 papers), Gastric Cancer Management and Outcomes (18 papers) and Cancer Treatment and Pharmacology (15 papers). Dieter Koeberle is often cited by papers focused on Colorectal Cancer Treatments and Studies (34 papers), Gastric Cancer Management and Outcomes (18 papers) and Cancer Treatment and Pharmacology (15 papers). Dieter Koeberle collaborates with scholars based in Switzerland, Germany and France. Dieter Koeberle's co-authors include Piercarlo Saletti, Thomas Ruhstaller, Richard Herrmann, G. Bodoky, Walter Mingrone, Markus Borner, Roger von Moos, Bernhard C. Pestalozzi, Beat Thuerlimann and Daniel Dietrich and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Dieter Koeberle

82 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dieter Koeberle Switzerland 23 1.6k 739 562 430 306 87 2.3k
Xiuyu Cai China 24 1.0k 0.6× 659 0.9× 282 0.5× 321 0.7× 291 1.0× 99 2.1k
Eli Avisar United States 19 1.4k 0.8× 377 0.5× 431 0.8× 567 1.3× 385 1.3× 72 2.2k
Mahmut Gümüş Türkiye 27 2.2k 1.4× 1.2k 1.6× 757 1.3× 376 0.9× 138 0.5× 174 3.7k
Kelly J. Lafaro United States 23 768 0.5× 420 0.6× 639 1.1× 289 0.7× 303 1.0× 81 1.7k
Ruth Vera Spain 24 1.3k 0.8× 394 0.5× 357 0.6× 283 0.7× 126 0.4× 102 1.8k
Jun‐Eul Hwang South Korea 25 663 0.4× 477 0.6× 580 1.0× 262 0.6× 144 0.5× 108 1.8k
Cristine Allmer United States 23 1.4k 0.9× 599 0.8× 693 1.2× 259 0.6× 275 0.9× 84 2.9k
Sanjeev A. Vasudevan United States 27 682 0.4× 426 0.6× 541 1.0× 311 0.7× 232 0.8× 118 2.2k
Callisia N. Clarke United States 22 789 0.5× 385 0.5× 404 0.7× 189 0.4× 301 1.0× 104 1.5k
Jeong Eun Kim South Korea 25 1.2k 0.7× 530 0.7× 466 0.8× 348 0.8× 93 0.3× 176 2.2k

Countries citing papers authored by Dieter Koeberle

Since Specialization
Citations

This map shows the geographic impact of Dieter Koeberle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dieter Koeberle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dieter Koeberle more than expected).

Fields of papers citing papers by Dieter Koeberle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dieter Koeberle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dieter Koeberle. The network helps show where Dieter Koeberle may publish in the future.

Co-authorship network of co-authors of Dieter Koeberle

This figure shows the co-authorship network connecting the top 25 collaborators of Dieter Koeberle. A scholar is included among the top collaborators of Dieter Koeberle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dieter Koeberle. Dieter Koeberle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Stintzing, Sebastian, Jan Wierecky, Axel Wein, et al.. (2024). Encorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: First effectiveness data of the European multi-centric, multi-national, non-interventional study—BERING-CRC.. Journal of Clinical Oncology. 42(16_suppl). 3551–3551. 1 indexed citations
3.
Güller, Ulrich, Stefanie Hayoz, Daniel Horber, et al.. (2024). 512O Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients: The phase III, prospective-randomized placebo-controlled multicenter SAKK 41/13 trial. Annals of Oncology. 35. S432–S432. 5 indexed citations
4.
Stintzing, Sebastian, Jan Wierecky, Helmut Forstbauer, et al.. (2023). Disease characteristics and clinical practice of BRAF V600E-mutant metastatic colorectal cancer treatment: Baseline analysis of patients enrolled in the BERING CRC study.. Journal of Clinical Oncology. 41(4_suppl). 34–34. 1 indexed citations
5.
6.
Joerger, Markus, Yannis Metaxas, Khalil Zaman, et al.. (2022). Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA). Cancers. 14(9). 2191–2191. 3 indexed citations
7.
Salvatore, Lisa, Emilio Bria, Isabella Sperduti, et al.. (2021). Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients’ data from 3 phase III studies. Cancer Treatment Reviews. 97. 102202–102202. 16 indexed citations
8.
McNamara, Mairéad G., Andre Lopes, Harpreet Wasan, et al.. (2020). Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. Journal of Hepatology. 73(5). 1109–1117. 29 indexed citations
9.
Salvatore, Lisa, Emilio Bria, Isabella Sperduti, et al.. (2019). Bevacizumab (BV) maintenance (M) after first-line chemotherapy (CT) plus BV for metastatic colorectal cancer (mCRC) patients (pts): A meta-analysis of individual pts data (IPD) from three phase III studies.. Journal of Clinical Oncology. 37(15_suppl). 3550–3550. 1 indexed citations
10.
Fox, Mark, Anne Christin Meyer‐Gerspach, Henriette Heinrich, et al.. (2018). Effect of cocoa on the brain and gut in healthy subjects: a randomised controlled trial. British Journal Of Nutrition. 121(6). 654–661. 9 indexed citations
11.
Fehr, Martin, Joachim Müller, Jürgen Fornaro, et al.. (2017). Early Postoperative FDG-PET-CT Imaging Results in a Relevant Upstaging in the pN2 Subgroup of Stage III Colorectal Cancer Patients. Clinical Colorectal Cancer. 16(4). 343–348. 3 indexed citations
12.
Moos, Roger von, Dieter Koeberle, Stefanie Hayoz, et al.. (2017). Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS -mutated rectal cancer: A phase I/II trial (SAKK 41/08). European Journal of Cancer. 89. 82–89. 20 indexed citations
13.
Koeberle, Dieter, Jean‐François Dufour, Gyula Demeter, et al.. (2016). Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Annals of Oncology. 27(5). 856–861. 102 indexed citations
14.
15.
Kasenda, Benjamin, Dieter Koeberle, Bernhard C. Pestalozzi, et al.. (2014). Survival in overweight patients with advanced pancreatic carcinoma: a multicentre cohort study. BMC Cancer. 14(1). 728–728. 37 indexed citations
16.
Hitz, Felicitas, Karin Ribi, Qiyu Li, et al.. (2013). Predictors of satisfaction with treatment decision, decision-making preferences, and main treatment goals in patients with advanced cancer. Supportive Care in Cancer. 21(11). 3085–3093. 21 indexed citations
17.
Joerger, Markus, Alwin D. R. Huitema, Dieter Koeberle, et al.. (2013). Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. Cancer Chemotherapy and Pharmacology. 73(1). 113–124. 7 indexed citations
18.
19.
Koeberle, Dieter, Roger von Moos, Sun Young Rha, et al.. (2008). Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. British Journal of Cancer. 98(7). 1204–1209. 66 indexed citations
20.
Gessner, U., et al.. (2000). Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate. Supportive Care in Cancer. 8(2). 115–122. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiuyu Cai Breakdown of academic impact, for papers by Eli Avisar Breakdown of academic impact, for papers by Mahmut Gümüş Breakdown of academic impact, for papers by Kelly J. Lafaro Breakdown of academic impact, for papers by Ruth Vera Breakdown of academic impact, for papers by Jun‐Eul Hwang Breakdown of academic impact, for papers by Cristine Allmer Breakdown of academic impact, for papers by Sanjeev A. Vasudevan Breakdown of academic impact, for papers by Callisia N. Clarke Breakdown of academic impact, for papers by Jeong Eun Kim
Rankless by CCL
2026